Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on radiopharmaceuticals for the diagnosis and treatment of cancer and rare diseases. Headquartered in Melbourne, Australia, the company is listed on the Australian Securities Exchange, and its American depositary shares trade on the Nasdaq under the ticker TLX.

Telix markets Illuccix, a kit for preparing a PSMA-targeted PET imaging agent used in prostate cancer, and has developed related imaging products. Its pipeline includes diagnostic imaging agents for kidney cancer and brain cancer, along with targeted radiation therapies that pair cancer-seeking molecules with therapeutic isotopes for prostate, kidney and brain cancers and other indications.

The company also operates radiopharmaceutical manufacturing and distribution capabilities, including Telix Manufacturing Solutions, to support production and supply of its products in the United States and other markets.